Abstract
Sterility testing and media fills are essential requirements in the pharmaceutical industry. With the results obtained the manufacturer must ensure that the aseptic filling process is under control. In an eight year (1988–1995) retrospective survey of three major Dutch pharmaceutical companies the performance of the sterility test, of media fills and their relationship have been statistically evaluated. The products included human and veterinary pharmaceuticals and biologicals, and were divided into six different groups according to their production process and primary containers. A distinction was made between the results from the period 1985–1991 and the period 1992–1995, because this made the statistical analyses of a number of types of products possible, and because some significant changes in the production process were made in 1991 at some of the production sites. The results of the evaluation of the sterility test show that the frequency of false positives has not changed significantly. The overall rate of false positives of 0.17% is a factor ten better than considered acceptable by USP XXIII. For all product groups the frequency of positive sterility tests has decreased during the period of investigation. During the period 1992–1995 there was no significant difference between the results of product sterility tests and the negative controls for any of the product groups. This indicates that given the present state-of-the-art production the sterility test offers little or no additional security. The overall contamination of the media fills done in the more recent period is a factor twenty better than the limit given in the PDA Technical Monograph No. 2. In the more recent period there is a good agreement between the observed positive rate of the sterility tests and the positive rate that had been estimated from the results of the media fills. This indicates that despite some shortcomings, media fills are an adequate simulation of the production process and can be used to give an estimate of the rejection rate for the various product groups. The overall conclusion is that the production conditions of the participating Dutch pharmaceutical companies comply with the current international guidelines for aseptic production and sterility testing.
Footnotes
- Received July 11, 1997.
- Accepted January 23, 1998.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.
